| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10548880 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US9763920 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US9757362 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US8486993 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US7994214 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US8617599 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US8889186 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US8591946 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US11077096 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US9161907 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US8623410 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US8586084 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US8623411 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US8889185 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(4 months from now) | |
| US10166190 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(4 years from now) | |
| US11110081 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(4 years from now) | |
| US11123331 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(4 years from now) | |
| US11419823 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(4 years from now) | |
| US10864199 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(4 years from now) | |
| US9549918 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(4 years from now) | |
| US8644239 | VELOXIS PHARMS INC | Method and apparatus for allocating and processing sequences in communication system |
Aug, 2028
(4 years from now) | |
| US8664239 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
Aug, 2028
(4 years from now) | |
| US8685998 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
Aug, 2028
(4 years from now) | |
Envarsus Xr is owned by Veloxis Pharms Inc.
Envarsus Xr contains Tacrolimus.
Envarsus Xr has a total of 23 drug patents out of which 0 drug patents have expired.
Envarsus Xr was authorised for market use on 10 July, 2015.
Envarsus Xr is available in tablet, extended release;oral dosage forms.
Envarsus Xr can be used as prophylaxis of organ rejection in de novo transplant patient, prophylaxis of organ rejection, prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations.
The generics of Envarsus Xr are possible to be released after 30 August, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 10, 2022 |
| Orphan Drug Exclusivity(ODE-94) | Jul 10, 2022 |
Drugs and Companies using
TACROLIMUS ingredient
Market Authorisation Date:
10 July, 2015Treatment:
Prophylaxis of organ rejection in de novo transplant patient; Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulationsDosage:
How can I launch a generic of ENVARSUS XR before its drug patent expiration?
More Information on Dosage
ENVARSUS XR family patents
